Suppression of interleukin-8 and myeloperoxidase production in the cerebrovascular bed during repeated deep hypothermic circulatory arrest

E Kuzumi*, A Vuylsteke*, A Downie*, JJ Dunning*, K McNeil* and DK Menon†

*Papworth Hospital, Cambridge, UK and †University of Cambridge, UK

Introduction: It has been suggested that mild hypothermia during cardiopulmonary bypass (CPB) may attenuate, but not completely suppress, the production of interleukin-8 (IL-8) in the brain [1]. This study examined the effect of repeated deep hypothermic circulatory arrest (DHCA) on production of IL-8 and myeloperoxidase (MPO) in the cerebrovascular bed in patients undergoing pulmonary thromboendarterectomy (PTE).

Methods: After LREC approval and written informed consent, we studied eight patients undergoing PTE. Anaesthetic and surgical technique were strictly standardized [2] and all patients had a jugular bulb catheter inserted after induction. After initiation of CPB, all patients were cooled to below 20°C and underwent at least two periods of DHCA for 20 min. Each DHCA period was separated by a 10-min reperfusion interval. The levels of IL-8 and MPO were measured in paired arterial and jugular samples drawn simultaneously at specific time points, using enzyme-linked immunoassay kits. Juguloarterial (j–a) gradients were then calculated. All data are expressed as median (interquartile range) and were compared with the baseline values using the Wilcoxon signed rank sum test. J–a gradients were compared with zero using one-sample t-test.

Results: The baseline arterial values before CPB [T1] for IL-8 and MPO were 12.9 (11.5–21.4) pg/ml and 4.5 (3.1–6.6) ng/ml, respectively (Fig. 1). For both IL-8 and MPO, arterial levels significantly increased before the first DHCA [T3] to 28.3 (21.6–43.1) pg/ml and 31.2 (26.1–11.7) ng/ml, respectively, and remained elevated until 8 min following the second DHCA [T7]. However, no significant j–a differences for IL-8 and MPO were found throughout this period.

Figure 1

IL-8 and MPO concentration during DHCA. T1, postinduction; T2, CPB started; T3, 2 min preDHCA1; T4, 1 min postDHCA1; T5, 8 min postDHCA1; T6, 1 min postDHCA2; T7, 8 min postDHCA2. *P < 0.05 versus baseline.

Conclusions: These data imply that the cerebral activation of inflammatory processes represented as specific IL-8 and MPO production in the cerebrovascular bed are suppressed during repeated DHCA in the present study.

References
Introduction: Silent myocardial ischaemia (SMI) has been shown to be temporally associated with tracheal extubation in up to 27% of patients after coronary artery bypass operations [1]. Patients who develop SMI during tracheal extubation are more likely to have a higher heart rate [1,2] and arterial pressure [2]. The aim of this study was to determine whether an esmolol infusion could affect the incidence of SMI during the weaning from intermittent positive pressure ventilation and tracheal extubation following coronary artery surgery. Patient haemodynamics and adverse events were also assessed.

Methods: Ethics Committee Approval and informed consent were obtained. The study was conducted in the intensive care unit (ICU) on patients who had undergone elective coronary artery surgery. Preoperative exclusion criteria were: digoxin therapy, electrocardiographic (ECG) evidence of left ventricular hypertrophy or left bundle branch block, cardiac pacemaker, asthma, a previous intolerance to beta adrenergic blockade or renal impairment. Postoperative exclusion criteria were first degree heart block or beta adrenergic agonist infusion at the time of study entry. Thirty-eight patients were randomized to the control group (group C) and 34 to receive a sliding scale infusion of esmolol (group E) with a target heart rate between 55–75 bpm. The study period extended from 120 min before until 180 min after tracheal extubation. Myocardial ischaemia, reversible ST segment depression ≥2 mm or elevation ≥3 mm for more than 60 s was detected using the Compas computerized ambulatory ECG system (S-pace Medical, Sheffield, UK). Heart rate and arterial pressure were recorded at 10-min intervals. A P value < 0.05 was considered significant.

Results: One patient from each group was withdrawn because of ECG lead faults. Two patients from group E were withdrawn because of hypotension. The patient characteristics were comparable between the two groups. The esmolol group had a lower incidence of myocardial ischaemia compared with the control group (3/31 versus 12/37; χ² analysis, P = 0.05). Heart rate increased in group C (analysis of variance, P = 0.002) and was unchanged in group E. Arterial pressure in both groups showed increases during tracheal extubation. Four patients from group E had a high heart rate that was difficult to control and a further three patients developed hypotension.

Conclusions: Esmolol does reduce the incidence of myocardial ischaemia in association with tracheal extubation following coronary artery surgery. However, the high incidence of adverse events limits its use in this patient population.

References

Table 1

<table>
<thead>
<tr>
<th>Exclusion criteria</th>
<th>Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-existing renal disease</td>
<td>Age above 80 years</td>
</tr>
<tr>
<td>Serum creatinine above 135 μmol/L</td>
<td>Unstable angina</td>
</tr>
<tr>
<td>LV ejection fraction less than 40%</td>
<td>Regular usage of nephrotoxic agents</td>
</tr>
<tr>
<td>Chronic or uncontrolled hypertension</td>
<td>Perioperative inotrope dependency</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td></td>
</tr>
</tbody>
</table>

in both groups throughout the study. A dramatic and similar rise in mean ± 2SD urinary RBP: creatinine ratio occurred in both groups peaking on day 1 (3183 ± 2534 versus 4035 ± 4078; P = 0.43) before returning to baseline levels. These trends were also observed with the urinary microalbumin:creatinine ratio (5.05 ± 2.66 versus 6.77 ± 5.76; P = 0.22). ONCAB patients had
a significantly more negative fluid balance on postoperative day 2
\(-183 \pm 1118 \text{ versus } 637 \pm 847 \text{ ml; } P < 0.05\).

Conclusions: Although renal dysfunction did not clinically occur in
any patient, sensitive indicators revealed significant and similar
injury to both renal tubules and glomeruli following either OPCAB
or ONCAB. These suggest that avoidance of CPB per se does not
offer additional renoprotection to patients at low risk of periopera-
tive renal insult during CABG.

Reference
‘renal-dose’ dopamine on renal tubular function following
cardiac surgery; assessed by measuring urinary retinol

What is the optimal paddle force for defibrillation?

CD Deakin, DM Sado, GW Petley and F Clewlow

Introduction: Firm paddle pressure during defibrillation is impor-
tant to minimize transthoracic impedance (TTI) and optimize trans-
myocardial current. Previous European Resuscitation Council
(ERC) guidelines recommended that 12 kg force should be used
[1] and the more recent International Liaison Committee on Resus-
citation (ILCOR) guidelines recommend ‘firm’ pressure [2]. The
actual relationship between force and transthoracic impedance has
not been established.

Methods: 55 patients (36 male, 19 female) undergoing general
anaesthesia for cardiac surgery were investigated. Male chests
were shaved. A pair of gel pads and paddles were placed in the
anterior–apical position according to the ILCOR guidelines. The
endotracheal tube was opened to air and paddles instrumented
with force sensors were applied to the chest wall with progressive
force to a maximum of 12 kgf. The resultant TTI was recorded at
10 measurements per second to a hard drive.

Results: Light pressure results in a high TTI that rapidly decreases
as paddle force increases (Fig. 1). An 18.7% fall in overall TTI
occurs when applying force from 0.5 to 6.0 kg. Increasing paddle
force from 6 to 12 kg results in a further decrease in TTI of 3.2%.

Conclusion: A minimum of 6 kg force applied to each paddle is
necessary to achieve 83% of the overall decrease in TTI seen at
12 kgf. Further decrease in TTI as force is applied in excess of
6 kgf is small and a force of 12 kgf only reduces TTI by a further
3.2% compared with TTI at 6 kgf. The additional clinical benefit of
applying 12 kgf as opposed to 6 kgf is questionable.

References
2. Deakin C, Petley G, Cardan E, Clewlow F: Does paddle force
applied during defibrillation meet advanced life support
guidelines of the European Resuscitation Council? Resusci-

Does a remifentanil bolus attenuate the haemodynamic response to rigid bronchoscopy?

NM Agnew, CNH Tan, NDA Scawn, SH Pennefather and GN Russell

The Cardiothoracic Centre, Liverpool NHS Trust, Liverpool, UK

Introduction: The pressor response to rigid bronchoscopy result-
ing in tachycardia and hypertension is well recognized. Patients
undergoing this procedure are often elderly and many have coexist-
ing cardiovascular impairment. Haemodynamic stability is therefore
 crucial. Propofol alone causes an initial drop in blood pressure,
which then rises above control levels after intubation with a signifi-
cant rise in the patients’ heart rate. Several studies have shown
that a remifentanil bolus attenuates the pressor response to intuba-
tion. The rapid recovery afforded by remifentanil is ideal for day-
case bronchoscopies. The aim of this prospective, double-blind,
randomized, controlled trial was to assess the efficacy of a remifen-
tagel bolus given before propofol in attenuating the haemodynamic
responses to rigid bronchoscopy.

Methods: Eighty patients were randomly assigned to receive a
bolus of one of four drugs: remifentanil 1 µg/kg, remifentanil
2 µg/kg, alfentanil 10 µg/kg or saline (control). The anaesthetist
was blinded to the solution used. Anaesthesia was then induced
with a target controlled infusion (TCU) of propofol, and suxa-
methonium (1.5 mg/kg) was used as relaxant. Heart rate and noninvasive
arterial pressures were recorded at minute intervals throughout the
procedure. Repeated measures analysis of variance and area
under curve analysis were used. Power analysis required 20
patients in each group to achieve a power of 0.9 and significance
of \( P < 0.05 \).

Results: Patient characteristics were similar. The TCI propofol
requirement was significantly higher in the saline group.
Changes in heart rate and arterial pressure were significantly higher in the saline group ($P = 0.0075$ and $P < 0.0001$, respectively; Fig. 1). No clinically significant difference was seen between the opioids. No patients complained of nausea and there were no differences in time to return of spontaneous ventilation, wake up times or use of rescue vasopressors.

**Conclusion:** An opioid bolus significantly attenuates the haemodynamic response to rigid bronchoscopy without delaying recovery. However, remifentanil, in a dose of either $1 \mu$g/kg or $2 \mu$g/kg, was not clinically superior to alfentanil $10 \mu$g/kg.

### The effect on coagulation parameters of the transfusion of cell saved blood after cardiac surgery

**V Bates, JMT Pierce, RS Gill and D O’Shaughnessy**  
*Southampton General Hospital, Southampton, UK*

**Introduction:** Intraoperative cell salvage (IOCS) minimizes exposure to donor blood. However, the process removes plasma and platelets and may worsen the coagulopathy induced by heparinization and cardiopulmonary bypass (CPB). Accordingly, we undertook a prospective observational study to examine the changes in coagulation parameters following the retransfusion of IOCS blood.

**Methods:** Following Regional Ethical Committee approval and written informed patient consent, 50 patients undergoing elective cardiac surgery were included.

**Table 1**

<table>
<thead>
<tr>
<th>Coagulation data</th>
<th>T1</th>
<th>T2</th>
<th>T3</th>
<th>p T1 versus T2</th>
<th>p T2 versus T3</th>
<th>p T1 versus T3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hb (g/l)</td>
<td>125 (14.6)</td>
<td>91.5 (12.8)</td>
<td>112.8 (15.5)</td>
<td>$&lt; 0.0001$</td>
<td>$&lt; 0.0001$</td>
<td>$&lt; 0.0001$</td>
</tr>
<tr>
<td>INR</td>
<td>1.1 (1.1–1.2)</td>
<td>1.7 (1.6–1.8)</td>
<td>1.5 (1.4–1.7)</td>
<td>$&lt; 0.0001$</td>
<td>$&lt; 0.0001$</td>
<td>$&lt; 0.0001$</td>
</tr>
<tr>
<td>APTTTR</td>
<td>1.1 (1.0–1.2)</td>
<td>1.33 (1.23–1.47)</td>
<td>1.26 (1.18–1.34)</td>
<td>0.001</td>
<td>0.010</td>
<td>0.005</td>
</tr>
<tr>
<td>Factor VII (U)</td>
<td>99 (21.6)</td>
<td>67 (17)</td>
<td>72 (20)</td>
<td>$&lt; 0.0001$</td>
<td>0.0046</td>
<td>$&lt; 0.0001$</td>
</tr>
<tr>
<td>Factor IX (U)</td>
<td>124 (107–136)</td>
<td>114 (107–132)</td>
<td>112 (101–127)</td>
<td>0.90</td>
<td>0.21</td>
<td>0.12</td>
</tr>
<tr>
<td>Fibrinogen (g/l)</td>
<td>3 (2.8–3.5)</td>
<td>2.1 (1.9–2.6)</td>
<td>2.2 (1.8–2.5)</td>
<td>$&lt; 0.0001$</td>
<td>0.7</td>
<td>$&lt; 0.0001$</td>
</tr>
<tr>
<td>Platelet count ($10^9$/l)</td>
<td>178 (48)</td>
<td>110 (40)</td>
<td>128 (39)</td>
<td>$&lt; 0.0001$</td>
<td>$&lt; 0.0001$</td>
<td>$&lt; 0.0001$</td>
</tr>
<tr>
<td>TEG MA (mm)</td>
<td>68 (66–70)</td>
<td>63 (60.5–68)</td>
<td>61 (59–63.5)</td>
<td>$&lt; 0.0001$</td>
<td>0.011</td>
<td>$&lt; 0.0001$</td>
</tr>
<tr>
<td>Antithrombin (U)</td>
<td>87 (83–93)</td>
<td>61 (10.9)</td>
<td>62 (11.7)</td>
<td>$&lt; 0.0001$</td>
<td>0.57</td>
<td>$&lt; 0.0001$</td>
</tr>
<tr>
<td>Activated protein C (U)</td>
<td>89.6 (17)</td>
<td>53 (12)</td>
<td>57 (13)</td>
<td>$&lt; 0.0001$</td>
<td>0.009</td>
<td>$&lt; 0.0001$</td>
</tr>
<tr>
<td>Albumin (g/l)</td>
<td>33 (30–33)</td>
<td>22 (21–23)</td>
<td>22.6 (3.7)</td>
<td>$&lt; 0.0001$</td>
<td>0.548</td>
<td>$&lt; 0.0001$</td>
</tr>
<tr>
<td>Calcium (mmol/l)</td>
<td>1.18 (1.16–1.2)</td>
<td>1.18 (1.15–1.9)</td>
<td>1.14 (0.06)</td>
<td>0.2639</td>
<td>0.0005</td>
<td>0.0007</td>
</tr>
</tbody>
</table>

Results are presented as means (SD) for normally distributed data and median (95%CI) for skewed data. Hb, haemoglobin; INR, international normalized ratio; APTTTR, activated partial thromboplastin time ratio; TEG MA, thromboelastogram maximum amplitude.
surgery were recruited. Cardiac anaesthesia, surgery and perfusion were conducted according to institutional protocols. CPB incorporated a Dideco D 903 oxygenator (Dideco S.p.A., Modena, Italy) with integral heat exchanger primed with 2 l Hartmann’s solution. IOCS was performed with a Dideco Compact Advanced Cell Saver. All shed mediastinal blood prior to heparinization and following protamine reversal was salvaged in addition to the CPB residue after the termination of CPB. Blood samples were drawn prior to incision (T1), 5 min after protamine reversal of heparin (T2) and 15 min after retransfusion of IOCS blood (T3), and analysed for ionised calcium, albumin, international normalized ratio, activated partial thromboplastin time ratio, factors VII and IX, fibrinogen, antithrombin, activated protein C, platelet count, haemoglobin, packed cell volume (PCV) and thromboelastogram. IOCS blood was analysed in five patients. Statistical analysis used the appropriate parametric and nonparametric tests. Significance was taken at the 5% level.

**Results:** Nine patients were given intraoperative blood or blood products and were excluded from further analysis. Of the remaining 41 patients (mean age 64.6 years and mean weight 84 kg), 35 were male. Mean CPB was 74 min and mean cross clamp was 46 min. The median volume of IOCS was 613 ml (7.3 ml/kg). There were almost undetectable amounts of coagulation factors present in IOCS blood. Table 1 presents the coagulation data.

**Conclusions:** IOCS blood in routine cardiac surgical practice raises the PCV to a point at which red cell transfusion is not necessary. There are no deleterious effects on coagulation. We recommend its routine use. To minimize unnecessary exposure to blood products, where transfusion is protocol driven, coagulation studies should follow IOCS blood transfusion.

**Acknowledgement:** This work was supported by a Haematology Educational Grant. There were no conflicts of interest.

---

**A randomized, controlled trial of blood conservation technologies in elective coronary artery bypass surgery**

NA McGill, D O’Shaughnessy, MJ Herbertson and RS Gill

Shackleton Department of Anaesthesia, Southampton General Hospital, Southampton, UK

**Objectives:** To assess the effectiveness of two mechanical methods of blood conservation in reducing the exposure to transfusion of allogenic red blood cells or any blood products during elective coronary artery bypass (CAB) surgery.

**Introduction:** The reduction of allogenic blood transfusion is a national priority. Acute Normovolaemic Haemodilution (ANH) and Intraoperative Cell Salvage (ICS) are two mechanical strategies used to achieve this. A recent meta-analysis of effectiveness of ICS [1] found no trials in cardiac surgery that employed these devices intraoperatively. ANH trials in cardiac surgery have been equivocal as to their benefit [2].

**Methods:** After local ethical approval and informed consent, 252 patients for routine CAB surgery were randomised into either a control group (who received a standard cardiac anaesthetic and operation), or an ICS group (where an ICS device was used during the operation and the residual circuit volume washed), or an ANH group (where 10 ml/kg of blood was extracted post induction and replaced with colloid, in addition to the use of an ICS device used as above). Outcome measures were proportions of patients exposed to allogenic blood or blood products and total units used. Standard transfusion thresholds were employed. Data was analysed using a non-parametric ANOVA.

**Results:** There were no significant differences between the three groups with respect to age, weight, Parsonnet score, bypass and cross-clamp times. Hospital length of stay, and median and total mediastinal drainage were similar across groups. Outcome measures (exposures, units of blood and \(P\) values) are shown in Table 1.

**Conclusions:** In elective CAB surgery, ICS significantly reduces the risk of exposure to allogenic blood and blood products. ANH does not confer any additional benefit.

**References**


**Table 1**

<table>
<thead>
<tr>
<th>Outcome measures</th>
<th>Control</th>
<th>ICS</th>
<th>(P) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposure to blood</td>
<td>51%</td>
<td>31%</td>
<td>0.015 (OR 0.43, 95% CI 0.23–0.80)</td>
</tr>
<tr>
<td>Exposure to any product</td>
<td>56%</td>
<td>38%</td>
<td>0.030 (OR 0.47, 95% CI 0.25–0.89)</td>
</tr>
<tr>
<td>Units of blood used</td>
<td>1.07 (0–8)</td>
<td>0.68 (0–11)</td>
<td>0.015</td>
</tr>
<tr>
<td>ANH</td>
<td></td>
<td>ICS</td>
<td></td>
</tr>
<tr>
<td>Exposure to blood</td>
<td>35%</td>
<td>31%</td>
<td>NS</td>
</tr>
<tr>
<td>Exposure to any product</td>
<td>39%</td>
<td>38%</td>
<td>NS</td>
</tr>
<tr>
<td>Units of blood used</td>
<td>0.63 (0–8)</td>
<td>0.68 (0–11)</td>
<td>NS</td>
</tr>
</tbody>
</table>

OR, odds ratio; CI, confidence interval. Units of blood are shown as median (min–max).
**In vitro variability in propofol absorption by different membrane oxygenators**

S Hickey, I Quasim and JD Gaylor*

Department of Anaesthesia, Glasgow Royal Infirmary, Glasgow and *Department of Bioengineering, University of Strathclyde, Glasgow, UK

**Introduction:** The sequestration of drugs, such as fentanyl [1,2], thiopental, nitroglycerine and propofol [3] in the extracorporeal circuit *in vitro* has been well described. This phenomenon can change the pharmacokinetic behaviour of drugs during cardiopulmonary bypass, thus potentially leading to problems in achieving adequate dosing regimens.

**Objective:** The aim of this *in vitro* laboratory study was to compare the binding of propofol to different oxygenator membranes, and to examine the effects of the type of prime solution and temperature on the rate of binding.

**Methods:** Samples of three types of membrane oxygenators were used: the SM-35 (polydimethylsiloxane in sheet form), the CML (polypropylene in sheet form) and the SAFE II (polypropylene in hollow fibre form). $^{14}$C-propofol in either crystalloid solution or diluted bovine blood was incubated with samples of membranes at 28°C or 37°C. Membrane samples were removed at 30, 60, 90 and 120 min and rinsed. The mass of propofol bound to the various membranes was then measured using liquid scintillation counting. This experiment was carried out for both types of prime solution at 28°C and 37°C.

**Results:** See Table 1. The SM-35 membrane bound significantly more propofol than the membranes from the CML and the SAFE II. Binding of propofol in diluted blood was significantly less than in crystalloid solution. Temperature had little effect on propofol binding in either prime solution type.

**Table 1**

<table>
<thead>
<tr>
<th>Membrane (surface area)</th>
<th>Crystalloid solution mass (mg/membrane*)</th>
<th>Diluted blood mass (mg/membrane*)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>28°C</td>
<td>37°C</td>
</tr>
<tr>
<td>SM-35 (3.5 m$^2$)</td>
<td>120</td>
<td>113.4 ± 2.80</td>
</tr>
<tr>
<td>CML (3.0 m$^2$)</td>
<td>120</td>
<td>6.30 ± 1.80</td>
</tr>
<tr>
<td>SAFE II (2.0 m$^2$)</td>
<td>120</td>
<td>23.60 ± 1.00</td>
</tr>
</tbody>
</table>

*Mean ± SD mass of propofol which could be bound by membrane of intact oxygenator, $n=5$ (based on mass of propofol bound per cm$^2$ of membrane)

**References**